4,000 Shares in ClearPoint Neuro, Inc. $CLPT Purchased by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. purchased a new stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 4,000 shares of the company’s stock, valued at approximately $48,000.

Several other large investors also recently made changes to their positions in the business. Goldman Sachs Group Inc. raised its holdings in shares of ClearPoint Neuro by 98.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock worth $3,066,000 after purchasing an additional 127,823 shares in the last quarter. Deutsche Bank AG bought a new stake in ClearPoint Neuro during the first quarter worth approximately $63,000. Lane Generational LLC grew its position in ClearPoint Neuro by 6.8% in the second quarter. Lane Generational LLC now owns 258,427 shares of the company’s stock worth $3,086,000 after buying an additional 16,382 shares during the last quarter. AlphaQuest LLC grew its position in ClearPoint Neuro by 433.5% in the second quarter. AlphaQuest LLC now owns 9,411 shares of the company’s stock worth $112,000 after buying an additional 7,647 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of ClearPoint Neuro in the second quarter valued at $445,000. Institutional investors own 30.08% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CLPT. Wall Street Zen downgraded ClearPoint Neuro from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, ClearPoint Neuro currently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Insider Buying and Selling

In related news, CEO Joseph Burnett sold 26,463 shares of the business’s stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $26.98, for a total transaction of $713,971.74. Following the transaction, the chief executive officer directly owned 217,059 shares of the company’s stock, valued at approximately $5,856,251.82. The trade was a 10.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.97% of the company’s stock.

ClearPoint Neuro Stock Down 5.0%

NASDAQ:CLPT opened at $13.74 on Tuesday. The business’s fifty day moving average price is $20.60 and its 200 day moving average price is $14.65. The firm has a market capitalization of $390.53 million, a price-to-earnings ratio of -16.96 and a beta of 1.28. The company has a current ratio of 7.30, a quick ratio of 6.45 and a debt-to-equity ratio of 1.46. ClearPoint Neuro, Inc. has a 1-year low of $9.76 and a 1-year high of $30.10.

ClearPoint Neuro (NASDAQ:CLPT) last released its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $5.36 million for the quarter, compared to analysts’ expectations of $9.60 million. ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. ClearPoint Neuro has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.